Publications

Society for Immunotherapy of Cancer (SITC)

November 19, 2024

OPB-101: A mesothelin-specific CAR T cell therapy leveraging protein design to enhance T cell proliferation and persistence for the treatment of ovarian cancer.

Society for Immunotherapy of Cancer (SITC)

OPB-101: A mesothelin-specific CAR T cell therapy leveraging protein design toenhance T cell proliferation and persistence for the treatment of ovarian cancer.

Related Articles

No items found.

Connect With Us

Email Us

Join the team

Join the Outpace team as we unleash the full potential of cells to cure.

See Open Positions

Work together

Outpace Bio collaborates with leading biopharma and academics who share our vision of creating a future where all cell therapies are effective and safe.

Collaborate
Our ScienceOur StoryNews
Connect
Terms of UsePrivacy PolicyUnsolicited Content

© Outpace Bio 2024

Outpace Bio, Inc. 700 Dexter Ave N, STE 300, Seattle, WA 98109